The multi-specific V H -based Humabody CB213 co-targets PD1 and LAG3 on T cells to promote anti-tumour activity.
Carolyn J EdwardsAngelica SetteCarl CoxBarbara Di FioreChris WyreDaniela SydorukDavid YadinPhilip HayesSzymon StelterPhillip D BartlettMiren ZuazoMaria Jesus Garcia-GrandaGiovanni BenedettiStratoniki FiaskaNeil R BirkettYumin TengCarrie EneverHugo ArasanzAna BocanegraLuisa ChocarroGonzalo Fernández-HinojalRuth VeraBethan ArcherIsabelle OsuchMartyna LewandowskaYasmin M SuraniGrazyna KochanDavid EscorsJames LeggAndrew J PiercePublished in: British journal of cancer (2021)
CB213 is poised to enter clinical development and, through intercepting both PD1 and LAG3 resistance mechanisms, may benefit patients with tumours escaping front-line immunological control.
Keyphrases